AZD5363

Catalog No.S8019

AZD5363 Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. AZD5363 purchased from Selleck.

    (A) 239 cells stably expressing Flag-IL-17RA (293-IL-17RA cell line) were treated with 2 μM AZD5363 (a pan-Akt inhibitor) and/or 50 ng/ml insulin for the indicated time periods; Western blot analysis was performed for the indicated proteins; exogenous, IL-17RA transfected into 293 cells; endogenous, endogenous IL-17RA expressed in 293 cells.

    Oncotarget, 2016, 7(12):13651-66. AZD5363 purchased from Selleck.

  • Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. AZD5363 purchased from Selleck.

    LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. AZD5363 purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M3PJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vIXlIxOCCwTR?= MnrzOkBl NEG1XppqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= MXuyOlM2OTN{Mx?=
ZR75 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnTW29uOTByIH7N MnXtOkBl M{e0OYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= MWmyOlM2OTN{Mx?=
T74D MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5NVAxKG6P NXS2bGd[PiCm NV34SGhDcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M4[zOlI3OzVzM{Kz
1%MCF7 NUW4[JBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfsOFAxKG6P NYrPeVBWPiCm MYHpcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? Mm\jNlY{PTF|MkO=
MCF7 LTED NWm2dmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyNFAhdk1? MnLrOkBl NYXV[JRKcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 MVeyOlM2OTN{Mx?=
ZR75 LTED NUf5RokyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[4THhtOTByIH7N Ml3POkBl M4rsd4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NVG0dJp2OjZ|NUGzNlM>
T74D LTED NFrXOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNFAhdk1? NIixRmc3KGR? NXjBPJNQcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M13qOFI3OzVzM{Kz
TamR NWKxXXlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoOFAxKG6P MlzlOkBl M13DfYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NX\pXW93OjZ|NUGzNlM>
HCC1954 NYWzd2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qyeVAuOS5|NTFOwG0> MXq1JIQ> MnHV[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? M3vi[FI3ODl3NEe1
BT474c NIXUSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjPNE0yNjN3IN88US=> NHXDdlM2KGR? MnLK[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? MYSyOlA6PTR5NR?=
KPL4 NYLle3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCNE0yNjN3IN88US=> M1rlelUh\A>? M1nmOoVvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz Mn7HNlYxQTV2N{W=
SKBR3 NXfaeFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXNE0yNjN3IN88US=> NXzFSWM6PSCm NV3aUZZL\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= MnftNlYxQTV2N{W=
MR49C NIn2d4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPiTIhpOC13IN88US=> M1PjRVQ5KGh? NXTlNIhMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1vBbFI2OTVzMEGy
MR49F NWXLboNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqwMVUh|ryP M{nSVVQ5KGh? Mn7WbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NE\YdZUzPTF3MUCxNi=>
NCI-H522 NX32ZZlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL4SnQ{UUN3ME2xNU4{KCkEsUKuO{kh|ryP NHL5PZczPDl3N{[4Ni=>
PC-9 NUPWT4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPXTWM2OD17LkOgLOKyOS5{KTFOwG0> M2rzd|I1QTV5Nkiy
NCI-H522 NGrDZmdHfW6ldHnvckBCe3OjeR?= NH;aPHUyNzVxMUCg{txO MoPIOE8zPCCq NXT1S2J1cW6lcnXhd4V{KEGNVDDwbI9{eGixconsZZRqd25? MXmyOFk2PzZ6Mh?=
PC-9 M2\I[GZ2dmO2aX;uJGF{e2G7 M2fhVVEwPS9zMDFOwG0> NH6wUZo1NzJ2IHi= NHTH[2JqdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? MmDWNlQ6PTd4OEK=
HGC27 NUn0bYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\qTWM2OD1yLkS0OUDPxE1? MojBNlQxQDh|OEK=
IM95m NGjxdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojpTWM2OD1yLkWxJO69VQ>? M{nWWFI1ODh6M{iy
AGS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;4TmlEPTB;MD61OVIh|ryP NXXYS5pZOjRyOEizPFI>
NCI-N87 M4\qfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwMEO3JO69VQ>? NYDYOoNiOjRyOEizPFI>
23132/87 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD1zLk[3NUDPxE1? MkDDNlQxQDh|OEK=
MKN1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHvR5ZKSzVyPUKuOFIyKM7:TR?= M1PjdFI1ODh6M{iy
SNU-620 M2[yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxTWM2OD1|LkO4OEDPxE1? MnjrNlQxQDh|OEK=
SNU-638 NV2wTI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwNUKzJO69VQ>? MVKyOFA5QDN6Mh?=
SNU-1 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\5TlNKSzVyPUWuNlU5KM7:TR?= Ml7TNlQxQDh|OEK=
SNU-601 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fTXGlEPTB;NT65N|gh|ryP NHrTU5UzPDB6OEO4Ni=>
SNU-668 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4cII5UUN3ME22MlAxOyEQvF2= M2nMclI1ODh6M{iy
HS746T NUTmNmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmxcHNTUUN3ME22MlA5PCEQvF2= NIPDTXQzPDB6OEO4Ni=>
KATO III M2HyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH1TWM2OD15LkK2O{DPxE1? MmK0NlQxQDh|OEK=
SNU-484 NVrkfVFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrCTWM2OD15LkO5NkDPxE1? MVKyOFA5QDN6Mh?=
SNU-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;WTmlEPTB;MUGuNFk4KM7:TR?= MoHVNlQxQDh|OEK=
OCUM-1 NWXWfVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LjU2lEPTB;MUSuOVE2KM7:TR?= NH\COmgzPDB6OEO4Ni=>
NUGC-3 NYniWFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrEbmZTUUN3ME2yNU45PzNizszN NEPxO4IzPDB6OEO4Ni=>
AZ521 M37IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ3LkS0PEDPxE1? MYOyOFA5QDN6Mh?=
SNU-216 NUXrZY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LqfmlEPTB;M{Cg{txO NE\uTWozPDB6OEO4Ni=>
NUGC-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17memlEPTB;M{Cg{txO NEHDUXQzPDB6OEO4Ni=>
SNU-5 NXLQZ21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNyIN88US=> NI\aR5YzPDB6OEO4Ni=>
GTL-16 NW\iblh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjNfFZJUUN3ME2zNEDPxE1? NVLyNGtYOjRyOEizPFI>
MKN74 NF7Yd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNyIN88US=> NWPoN2RMOjRyOEizPFI>
PAMC82 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjoZlJKSzVyPUOwJO69VQ>? MYmyOFA5QDN6Mh?=
LNCaP MVjGeY5kfGmxbjDBd5NigQ>? MkPNOUDPxE1? NFnITJUxNTJ2IHi= MU\pcoR2[2W|IFHLWHM1PzNiYX7kJGFMXFR|MEigdIhwe3Cqb4L5cIF1cW:wIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M3PaN|I{QTZ4NkKx
C4-2  MkOySpVv[3Srb36gRZN{[Xl? M3fyfFUh|ryP MVuwMVI1KGh? M3e1bIlv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M{\YV|I{QTZ4NkKx
LNCaP M2\kVGZ2dmO2aX;uJGF{e2G7 MV:1JO69VQ>? M1u5fFAuOjRiaB?= NIWw[mJqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhfGinIHTpd5RidCCDS2StdIF1cHejeTDibY9u[XKtZYLzJIlv[2y3ZHnu[{BRWkGVNECsJIVKTjSHLDC0SU1DWDFuIH3UU3ItKGGwZDDQO|AhWzZia3nuZZNmKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz M1HxWVI{QTZ4NkKx
C4-2  NFTHbGFHfW6ldHnvckBCe3OjeR?= NFHleHg2KM7:TR?= NVHoSVA4OC1{NDDo MnHsbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCmaYP0ZYwhSUuWLYDheIh4[XliYnnvcYFzc2W{czDpcoNtfWSrbnegVHJCWzRyLDDlTWY1TSxiNFWtRnAyNCCvVF;SMEBidmRiUEewJHM3KGurbnHz[UBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MXKyN|k3PjZ{MR?=
LNCaP M2mxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy3eYwyNTFyMECwJI5O M2\v[VAuOyCm MlfJbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1TpN|I{QTZ4NkKx
C4-2  NVz5eXlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexMVExODByIH7N NVHvXmJQOC1|IHS= MoKzbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NUPk[Ig1OjN7Nk[2NlE>
LNCaP MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXlNVAxNTVyMECgcm0> M37sdlczKGh? NWLlb5JJcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> MVKyN|k3PjZ{MR?=
C4-2  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f6flExOC13MECwJI5O NIDMWYk4OiCq NYTCN2pQcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> MWiyN|k3PjZ{MR?=
PC-3 NFTMOGlHfW6ldHnvckBCe3OjeR?= M3ntRVAvPS9zL{GwJO69VQ>? NGXYSFU1QCCq NGDzTnVld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NULXXFdpOjN{NUi3OFA>
DU145  NInN[5dHfW6ldHnvckBCe3OjeR?= NEW5N3UxNjVxMT:xNEDPxE1? M3rWOFQ5KGh? M3vEO4Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKHCjdHj3ZZkheHKxdHXpcpMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlPaNlMzPTh5NEC=
LNCaP NHH5fmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHvxVFQxNTFyMECgcm0> MojvNE01KGR? MoL3doVlfWOnZDDMUmNiWCClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NEXSPVAzOzJ3OEe0NC=>
PC-3  NHfj[ZhHfW6ldHnvckBCe3OjeR?= NFTPO3gyOCEQvF2= NH\w[4cyOiCq M{C0c4lv\HWlZYOgZZV1d3CqYXf5 M4DjWFI{OjV6N{Sw

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% CMC Na
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02576444 Recruiting Cancer Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|Yale University November 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT02664935 Recruiting Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centre Network March 2015 Phase 2
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 2015 Phase 2
NCT02525068 Recruiting Adenocarcinoma of the Prostate Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust December 2014 Phase 2
NCT02208375 Recruiting Breast Cancer|Malignant Female Reproductive System Neoplasm M.D. Anderson Cancer Center|AstraZeneca|National Cancer Institute (NCI) November 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy AZD5363 | AZD5363 supplier | purchase AZD5363 | AZD5363 cost | AZD5363 manufacturer | order AZD5363 | AZD5363 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID